Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355213 | 1.00 | ACE (0.55) | ACEPTPN1ITGB3ITGA2BITGB1 | |
| SCHEMBL9958960 | 1.00 | ACE (0.55) | ACEPTPN1ITGB3ITGA2BITGB1 | |
| SCHEMBL1743843 | 0.93 | ACE (0.55) | ACEPTPN1ITGB3ITGA2BITGB1 | |
| SCHEMBL11736921 | 0.89 | CTSS (0.47) | ACEPTPN1HPGDSMN1; SMN2CTSS | |
| SCHEMBL8248143 | 0.88 | CYP3A4 (0.48) | HPGDSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL16460097 | 0.87 | SMN1; SMN2 (0.46) | ACEHPGDSMN1; SMN2CTSSCTSK | |
| SCHEMBL16460098 | 0.87 | SMN1; SMN2 (0.46) | ACEHPGDSMN1; SMN2CTSSCTSK | |
| SCHEMBL25132031 | 0.86 | TAAR1 (0.58) | HPGDSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL25132143 | 0.86 | TAAR1 (0.58) | HPGDSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL6719702 | 0.85 | SMN1; SMN2 (0.46) | HPGDSMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731211-A1 | ALLYL- AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS | Definium Therapeutics US, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250312309-A1 | ALLYL-AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS | Mind Medicine, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-2024263978-A1 | ALLYL- AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS | Mind Medicine, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-109134481-B | Substituted pyrrole chromone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中山大学 | 2021-05-14 | — | — | CN | disclosed |
| EP-2655322-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | Diverchim (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085474-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | DIVERCHIM (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | ACE 457/4885PTPN1 4445/4885ITGB3 3500/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | ACE 458/4885PTPN1 4361/4885ITGB3 4109/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ACE 1529/4885PTPN1 4311/4885ITGB3 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.